CELUW
Celularity IncKey Statistics
About Celularity Inc
Celularity Inc (CELUW) is an innovative clinical-stage biotechnology company focused on developing cutting-edge cell therapies leveraging the unique regenerative properties of human placental cells. With a strategic emphasis on addressing critical health challenges, including cancer, autoimmune disorders, and degenerative diseases, Celularity's proprietary technology platform supports the creation of off-the-shelf therapies, enhancing accessibility for patients. The company's robust pipeline, underpinned by a strong portfolio of intellectual property, positions it favorably within the dynamic landscape of cell-based medicine, aiming to meet the increasing demand for transformative therapeutic options in areas of significant unmet medical need.
Fundamentals
| Revenue (TTM) | $26.55M |
| Gross Profit (TTM) | $6.48M |
| EBITDA | $-54.01M |
| Operating Margin | -492.10% |
| Return on Equity | -6367.00% |
| Return on Assets | -30.90% |
| Revenue/Share (TTM) | $1.04 |
| Book Value | $-0.71 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | -61.30% |
| Quarterly Revenue Growth (YoY) | -77.40% |
| Shares Outstanding | 0 |
| Float | $18.82M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |